Medicare demands PBM transparency—but keeps the details secret

What it does

This bill requires pharmacy benefit managers (PBMs)—the middlemen who negotiate drug prices and manage prescription benefits for Medicare Part D plans—to submit detailed annual reports to Medicare starting in 2028, disclosing drug pricing, rebates, affiliate relationships, and cost comparisons. The reports must be machine-readable and available to plan sponsors, auditors, and federal oversight bodies (CMS, GAO, CBO, MedPAC), with strict confidentiality rules preventing public identification of specific PBMs, plans, or drug prices. Seniors and plan sponsors gain transparency into how PBMs negotiate and retain revenue; PBMs face audit rights and enforcement penalties for non-compliance.

Why we flagged it

The bill's core function is to mandate detailed PBM reporting and audit rights to increase transparency in Medicare drug pricing and rebate practices. While framed as 'saving seniors money,' the mechanism is transparency-focused rather than price-capping; the civic benefit flows from accountability and information access, not direct cost reduction.

What the text implies

• PBMs may shift opaque practices to affiliate structures or service-fee arrangements not fully captured by the reporting requirements, potentially obscuring true cost flows.
• The 2028 implementation delay gives PBMs three years to restructure contracts and affiliate relationships before reporting begins, potentially reducing the bill's transparency impact.

The full analysis lists 5 implications of this text.

Who stands to gain

Medicare Advantage and Part D plan sponsors (via audit rights and cost transparency); Independent pharmacies and non-affiliated pharmacy networks (via disclosure of affiliate dispensing; Generic and biosimilar manufacturers (via required disclosure of formulary tier disparities vs. bran